RCS - Agronomics Limited - Capital Markets Portfolio Company Presentations

AgronomicsAnnouncement

12/02/2024 11:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240212:nRSL8208Ca&default-theme=true

RNS Number : 8208C  Agronomics Limited  12 February 2024

RNS Reach

12 February 2024

Agronomics (https://agronomics.im/) (https://agronomics.im/) Limited
(https://agronomics.im/)

("Agronomics" or the "Company")

Capital Markets Portfolio Company Presentation Series

Agronomics (LON: ANIC), a leading listed company in cellular agriculture, is
pleased to announce it will be hosting a Capital Markets Investor Presentation
series.

The series will comprise individual presentations from industry-leading
companies within the cell culture and precision fermentation sector within the
Agronomics portfolio. For each presentation, the portfolio company's
management team will provide in-depth insight into the purpose, market demand,
technical milestones and growth strategy of the company, together with a
Q&A session at the end of the presentation. The Company expects a
presentation to be held, on average, every eight weeks.

The first presentation will be held with the senior management team at Meatly
on 28 February 2024, at 15:00 GMT.

Agronomics invested £1.2 million into Meatly since its inception, and which
is currently carried at £4.96 million. This position accounts for
approximately 3% of Agronomics' last published Net Asset Value (31/12/23)
(https://polaris.brighterir.com/public/agronomics/news/rns/story/xop7j9r) .
Agronomics has an equity ownership of 40.7% on a fully diluted basis.

Meatly aims to develop the first-ever cultivated meat products for the £80
billion pet food industry. The company is creating pet food that is healthy,
ethical, and sustainable. Its groundbreaking product is free from antibiotics
and steroids. To date, the company continues to set new benchmarks for the
industry reducing costs and scaling production in record time. To date, it has
removed all animal components from the manufacturing process, has developed
prototype products, and built relationships with leading pet food
manufacturers and retailers. It has begun feeding trials and aims to release
its product in the UK in H1 2024.

Attendees are able to register for the event using the following
(https://us02web.zoom.us/webinar/register/WN_rsloZoXGS9qmMy5ZMOZoyw) link
(https://us02web.zoom.us/webinar/register/WN_rsloZoXGS9qmMy5ZMOZoyw)
(https://us02web.zoom.us/webinar/register/WN_rsloZoXGS9qmMy5ZMOZoyw#/registration
(https://us02web.zoom.us/webinar/register/WN_rsloZoXGS9qmMy5ZMOZoyw#/registration)
). After registering, attendees will receive a confirmation email containing
information about joining the webinar.

About Agronomics (https://agronomics.im/)

Agronomics is a leading listed alternative proteins company with a focus on
cellular agriculture including precision fermentation and cultivated meat. The
Company has established a portfolio of over 20 companies in this rapidly
advancing sector. It seeks to secure minority stakes in companies owning
technologies with defensible intellectual property that offer new ways of
producing food and materials with a focus on products historically derived
from animals. These technologies are driving a major disruption in
agriculture, offering solutions to improve sustainability, as well as
addressing human health, animal welfare and environmental damage. This
disruption will decouple supply chains from the environment and animals, as
well as being fundamental to feeding the world's expanding population. A full
list of Agronomics' portfolio companies is available at
(https://clicktime.symantec.com/368cVqxx3R6vTFuHpf6MSE66Gi?u=https%3A%2F%2Fagronomics.im%2F)
https://agronomics.im/ (https://www.agronomics.im/) .

About Cellular Agriculture

We define cellular agriculture as the direct production of agricultural
commodities from living cells or single-celled organisms in a process
completely disconnected from conventional agriculture. This encompasses cell
culture, including cultivated meat and seafood, fermentation - including
biomass and precision fermentation, and enabling technologies, such as novel
bioreactor designs and low-cost growth factor methodologies to support the
first two categories. These enabling technologies aim to provide more
efficient methods for the development of cellular agriculture products,
reducing greenhouse gas emissions, antibiotic requirements, land use, water
use, energy use, improving animal welfare, and mitigating climate change.

For further information please contact:

 Agronomics           Beaumont              Canaccord Genuity Limited       Cenkos                Peterhouse Capital    SEC Newgate

 Limited              Cornish Limited                                       Securities Plc        Limited
 The Company          Nomad                 Joint Broker                    Joint Broker          Joint Broker          Public Relations
 Jim Mellon           Roland Cornish        Andrew Potts                    Giles Balleny         Lucy Williams         Bob Huxford

 Anthony Hughes
 Denham Eke           James Biddle          Harry Pardoe                    Michael Johnson       Charles Goodfellow

                                            Alex Aylen (Head of Equities)
 +44 (0) 1624 639396  +44 (0) 207 628 3396  +44 (0) 207 523 8000            +44 (0) 207 397 8900  +44 (0) 207 469 0936  agronomics@secnewgate.co.uk

 info@agronomics.im

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABLLFFZLLZBBX